- Tel: 858.663.9055
-
Email: info@nsjbio.com
- Tel: 858.663.9055
- Email: info@nsjbio.com
Related Products
|
Tumor necrosis factor ligand superfamily member 15 (TNFSF15), commonly known as TL1A or VEGI, is a cytokine belonging to the TNF ligand superfamily involved in immune regulation, inflammatory signaling, endothelial biology, and T-cell activation pathways. TL1A Antibody / TNF Superfamily Cytokine Antibody recognizes a secreted and membrane-associated cytokine that functions through interaction with death receptor 3 (DR3/TNFRSF25) to regulate immune activation and inflammatory signaling responses.
TL1A antibody, also referred to as TNFSF15 antibody and VEGI antibody in the literature, is widely used in immunology, inflammatory disease, and cytokine signaling research. Clone rVEGI/1283 recombinant rabbit monoclonal antibody supports investigation of TNF superfamily signaling pathways associated with mucosal immunity, T-cell regulation, autoimmune disease, and inflammatory tumor microenvironments.
TL1A is primarily expressed by endothelial cells, activated antigen-presenting cells, macrophages, dendritic cells, and inflammatory immune cell populations. Binding of TL1A to DR3 activates downstream NFkB and MAPK signaling pathways that promote T-cell proliferation, cytokine production, and inflammatory amplification responses. Elevated TL1A expression has been strongly associated with inflammatory bowel disease, Crohn disease, ulcerative colitis, rheumatoid arthritis, psoriasis, and additional chronic inflammatory disorders.
In cancer and vascular biology research, TNFSF15 has also been investigated for roles in angiogenesis regulation, endothelial signaling, and immune microenvironment modulation. Earlier literature frequently referred to TNFSF15 as VEGI because of its reported anti-angiogenic activity in endothelial cell systems. More recent studies increasingly emphasize TL1A as an immunoregulatory cytokine involved in mucosal inflammation and adaptive immune signaling.
Analysis of HuProt(TM) protein microarray containing more than 19,000 full-length human proteins demonstrated highly selective binding of clone rVEGI/1283 to TNFSF15. The markedly elevated Z-score and S-score support exceptionally strong target specificity relative to unrelated proteins present on the array, supporting the utility of this recombinant rabbit monoclonal antibody for selective TL1A detection in immune signaling and cytokine biology research applications.
Immunohistochemistry staining with TL1A antibodies commonly demonstrates cytoplasmic and extracellular-associated staining patterns in inflammatory or epithelial-associated cellular populations. Because TL1A signaling contributes to cytokine amplification and inflammatory pathway activation, antibodies targeting TNFSF15 are increasingly valuable tools in studies examining immune regulation, chronic inflammation, and therapeutic modulation of TNF superfamily signaling networks.
Together, the available immunohistochemistry and protein microarray specificity data support the use of TL1A antibody clone rVEGI/1283 for investigating inflammatory signaling, TNF superfamily cytokine biology, and immune regulatory pathways associated with chronic inflammatory disease and tumor immunology.
Explore additional Immunology Antibodies targeting TNF superfamily cytokines, inflammatory signaling mediators, and immune regulatory pathway proteins.
Titration of the TL1A Antibody / TNF Superfamily Cytokine Antibody may be required for optimal performance.
1. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.
A full length human recombinant protein was used as the immunogen for this TL1A antibody.
Store the TL1A antibody at 2-8oC (with azide) or aliquot and store at -20oC or colder (without azide).
TL1A antibody, TNFSF15 antibody, VEGI antibody, TNF ligand superfamily member 15 antibody, TNF superfamily cytokine antibody
Your bulk quote request has been submitted successfully!
Please contact us if you have any questions.